{
    "clinical_study": {
        "@rank": "75725", 
        "arm_group": [
            {
                "arm_group_label": "Pre-Transplant Cohort", 
                "description": "HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR\u220632 cord blood transplant"
            }, 
            {
                "arm_group_label": "Post-Transplant Cohort", 
                "description": "HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR\u220632 cord blood transplant"
            }
        ], 
        "biospec_descr": {
            "textblock": "For consenting participants, blood and tissue samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "IMPAACT P1107 will describe the outcomes of HIV-infected persons, ages 12 months and older,\n      who undergo transplantation with CCR5\u039432 cord blood stem cells for treatment of cancer,\n      hematopoietic disease, or other underlying disease."
        }, 
        "brief_title": "IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5\u039432 Donor Cells on HIV Persistence", 
        "completion_date": {
            "#text": "March 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed HIV-1 infection\n\n          -  12 months of age or older\n\n          -  Willing to provide written informed consent\n\n          -  Pre-Transplant Cohort: Underlying disease appropriate for stem cell transplant, as\n             determined by the transplant team as part of standard of care.\n\n          -  Pre-Transplant Cohort: Availability of an appropriately matched (as determined by the\n             transplant center) CCR5\u039432 cord blood unit (homozygous or heterozygous) and intention\n             to proceed with transplantation. NOTE:  Double cord transplants are allowed.  If a\n             double cord is used, at least one cord blood unit should be CCR5\u220632 (homozygous or\n             heterozygous).\n\n          -  Pre-Transplant Cohort:  Received a CCR5\u039432 homozygous cord blood or bone marrow\n             transplant within the last two years.\n\n        Exclusion Criteria:\n\n        \u2022 Received, or planning to receive, more than one CCR5\u039432 homozygous cord blood or bone\n        marrow transplant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Months", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "HIV-1 infected children and adults who undergo cord blood stem cell transplantation for\n        treatment of cancer, hematopoietic disease, or other underlying disease"
            }
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140944", 
            "org_study_id": "IMPAACT P1107", 
            "secondary_id": [
                "UM1AI068632", 
                "UM1AI068616", 
                "UM1AI106716"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cord blood transplantation", 
            "CCR5\u039432", 
            "HIV cure"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": {
            "url": "http://www.impaactnetwork.org/studies/P1107.asp"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "St Louis", 
                    "country": "United States", 
                    "state": "Missouri"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Rachel Presti, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "IMPAACT P1107: Cord Blood Transplantation With CCR5\u039432 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence", 
        "overall_contact": {
            "email": "acoletti@fhi360.org", 
            "last_name": "Anne Coletti, MS", 
            "phone": "919-544-7040", 
            "phone_ext": "11238"
        }, 
        "overall_official": {
            "affiliation": "University of California, Los Angeles", 
            "last_name": "Yvonne Bryson, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Survival and event-free survival at 100 days, Week 26, Week 52, and then every six months until five years post-transplant", 
                "measure": "Survival", 
                "safety_issue": "Yes", 
                "time_frame": "Through 5 years post-transplant"
            }, 
            {
                "description": "Graft versus host disease", 
                "measure": "Graft versus host disease", 
                "safety_issue": "Yes", 
                "time_frame": "Through 5 years post-transplant"
            }, 
            {
                "description": "Chimerism (\u2265 98% of blood cells bearing CCR5\u220632) and time to hematopoietic cell and immune recovery", 
                "measure": "Engraftment", 
                "safety_issue": "No", 
                "time_frame": "Through 5 years post-transplant"
            }, 
            {
                "description": "HIV-1 proviral DNA levels in peripheral blood", 
                "measure": "HIV DNA level", 
                "safety_issue": "No", 
                "time_frame": "Through 5 years post-transplant"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140944"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}